Intravesical hyaluronic acid in the treatment of refractory interstitial cystitis

Urology

Volumn 49, Issue 5 SUPPL., 1997, Pages 111-113

  Morales, Alvaro ^a,b   Emerson, Laurel ^a   Nickel, J Curtis ^a  

^a QUEEN S UNIVERSITY   (Canada)

^b KINGSTON GENERAL HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOSAMINOGLYCAN; HYALURONIC ACID;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HUMAN; INTERSTITIAL CYSTITIS; MAJOR CLINICAL STUDY; MICTURITION; PATIENT COMPLIANCE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SYMPTOMATOLOGY; TREATMENT PLANNING;

ADMINISTRATION, INTRAVESICAL; CYSTITIS, INTERSTITIAL; HUMANS; HYALURONIC ACID; PILOT PROJECTS;

EID: 0030982848     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(97)00183-0     Document Type: Article

References (26)

1. Parsons CL, Lilly JD, and Stein P: Epithelial dysfunction in non-bacterial cystitis (interstitial cystitis). J. Urol. 145: 732-735, 1991.
2. Ruggieri MR, Chelsky MJ, Rosen SI, Shikley TJ, and Hanno PM: Current findings and future research avenues in the study of interstitial cystitis. Urol Clin North Am 21: 163-176, 1994.
3. Anderstrom C, Fall M, andjohansson S: Scanning electron microscopic findings in interstitial cystitis. Br J Urol 63: 270-279, 1989.
4. Nickel JC, Emerson L, and Cornish J: The bladder mucus (glycosaminoglycan) layer in interstitial cystitis. J Urol 149: 716-718, 1993.
5. Sant G, Ucci A, and Alroy J: Bladder surface glycosa-minoglycans (GAG's) in interstitial cystitis. J Urol 135: 175A, 1986.
6. Ratliff TL, Klutke CG, and McDougall EM: The etiology of interstitial cystitis. Urol Clin North Am 21: 21-30, 1994.
7. Emtage J, Morales A, Heaton JPW, and Perez R: Heparin in the treatment of interstitial cystitis. J Urol 133: 168A, 1985.
8. Perez-Marrero R, Emerson L, Maharajh D, and Juma S: Prolongation of response to DMSO by heparin maintenance. Urology [Suppl] 41: 64-67, 1993.
9. Sant GR, and LaRock DR: Standard intravesical therapies for interstitial cystitis. Urol Clin North Am 21: 73-83, 1994.
10. Parsons CL: The therapeutic role of sulfated polysaccharides in urinary bladder. Urol Clin North Am 21: 93-100, 1994.
11. Pitsillides AA, Will RK, Bayliss MT, and Edwards JCW: Circulating and synovial fluid hyaluronan levels. Effects of intra-articular corticosteroid on the concentration and the role of turnover. Arth Rheum 7: 1030-1035, 1994.
12. Sharif M, George E, Shepstone L, Knudson W, Thonar EJM, Cushnagan J, and Dieppe P: Serum hyaluronic acid level as a predictor of disease progression in osteoarthritis of the knee. Arth Rheum 38: 760-764, 1995.
13. Houpt JB, Aviad A: Osteaoarthritis (OA) of the knee: effect of intra-articular (I.A.) sodium hyaluronate (HA). Clin Exp Rheumatol 4: 180-184, 1990.
14. Hurst RE, Rhodes SW, Adamson PB, Parsons CL, and Roy JB: Functional and structural characteristics of the glycosaminoglycans of the bladder luminal surface. J Urol 138: 433-437, 1987.
15. Morales A, Emerson L, Nickel JC, and Lundie M: Intravesical hyaluronic acid in the treatment of refractory interstitial cystitis. J Urol 156: 45-48, 1996.
16. Weiss C, Balasz AE, Onge R, and Denlinger JL: Clinical studies on intra-articular injection of Healon (sodium hyaluronate) in the treatment of osteoarthritis of human knees. Semin Arth Rheum [Suppl 1] 11: 143-147, 1980.
17. Goldberg RL, Huff JP, Lenz ME, Glickamn P, and Katz R et al.: Elevated plasma levels of hyaluronate in patients with osteoarthritis and rheumatoid arthritis. Arth Rheum 34: 799-803, 1991.
18. Sato H, Takahashi T, and Ide H: Antioxidant activity of synovial fluid, hyaluronic acid and two sub-components of hyaluronic acid. Synovial fluid scavenging effect is enhanced in rheumatoid arthritis patients. Arth Rheum 31: 63-67, 1988.
19. Balasz EA, and Denlinger JL: The role of hyaluronic acid in arthritis and its therapeutic use, in: Peyron JG (Ed.): Osteoarthritis: Current Clinical and Fundamental Problems. Basel, Geigy, 1984, pp 165-174.
20. Goldberg RL, and Toole BP: Hyaluronate inhibition of cell proliferation. Arth Rheum. 30: 769-773, 1987.
21. Abatangelo G, Martelli M, and Vecchia P: Healing of hyaluronic acid-enriched wounds: histological observations. J Surg Res 35: 410-414, 1983.
22. Hadler NM, and Napier MA: Structure of hyaluronic acid in synovial fluid and its influence on the movement of solutes. Sem Arth Rheum 7: 141-146, 1977.
23. Aviad AD, and Houpt JB: The molecular weight of therapeutic hyaluronan (sodium hyaluronate): how significant is it? J Rheumatol 21: 297-300, 1944.
24. Asheim A, and Lindblad G: Intra-articular treatment of arthritis in race horses with sodium hyaluronate. Acta Vet Scand 17: 379-383, 1976.
25. Holm-Bentzen M, Jacobsen F, Nerstrom B, Lose G, Kristensen JK, Pedersen RH, Krarup T, Feggetter J, Bates P, Barnard R, Larsen S, and Hald TA: Prospective double-blind clinically controlled multicenter trial of sodium pentosanpolysulfate in the treatment of interstitial cystitis and related painful bladder disease. J Urol 138: 503-507, 1987.
26. Fritjofsson A, Fall M, Juhlin R, Persson BE, and Ruutu M: Treatment of ulcer and non-ulcer interstitial cystitis with sodium pentosanpolysulfate: a multicenter trial. J Urol 138: 508-512, 1987.